arrow
T

Tapan M. Kadia

md anderson cancer center
H指数:89
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS

口服三联方案(地西他滨/西达苯胺、维奈克拉和吉列替尼)用于新诊断和复发/难治性FLT3突变急性髓系白血病及高风险骨髓增生异常综合征

2026-10-130
OAAI
Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms

Li-Fraumeni综合征合并髓系肿瘤的成人患者预后

Cancer
IF5.1
2026-09-180
OAAI
Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy

多组学生物标志物的纳入提高了接受高强度诱导化疗的急性髓系白血病患者的治疗反应、复发和总生存期的预测准确性

2026-09-170
OAAI
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

新诊断急性髓系白血病中NPM1突变相关的临床结局

Cancer
IF5.1
2026-08-130
OAAI
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

BRAF突变在急性髓系白血病中的预后和治疗意义

Leukemia
IF13.4
2026-06-150
OAAI
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

低强度治疗下急性髓系白血病中ASXL1突变的预后影响

Cancer
IF5.1
2026-05-060
OA
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis

Hyper-CVAD 与 Hyper-CVAD 联合 Blinatumomab(无论是否联合 Inotuzumab Ozogamicin)治疗新诊断费城染色体阴性急性淋巴细胞白血病成年患者的倾向性评分分析

2026-04-250
OAAI
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Blinatumomab和Ponatinib与Hyper-CVAD和Ponatinib在初诊费城染色体阳性急性淋巴细胞白血病的成人患者中的比较:一项倾向性评分分析

2026-04-010
PRE
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

克拉屈滨联合低剂量阿糖胞苷和维奈克拉,与阿扎胞苷和维奈克拉交替用于新诊断急性髓系白血病

2026-04-010
PRE
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome

POT1肿瘤易感综合征的临床、遗传及家族特征

Cancer
IF5.1
2026-02-130
OAAI
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

BET抑制剂为基础的组合,靶向MECOM重排(r) AML中的新型依赖性

Leukemia
IF13.4
2025-12-190
OAAI
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
Outcomes of Patients with IDH1-Mutated Myeloid Neoplasms Treated with Olutasidenib

IDH1突变髓系肿瘤患者接受Olutasidenib治疗后的临床结局

2025-12-100
PRE
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell/myeloid mixed phenotype acute leukemia

使用克拉屈滨、低剂量阿糖胞苷、维奈克拉和布林佐胺单抗的低强度化疗免疫疗法,可产生BCR::ABL1阴性B细胞/髓系混合表型急性白血病患者的高缓解率。

2025-12-011
OA
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

早期造血细胞群内的快速克隆选择预示ivosidenib联合治疗的结局

Blood
IF23.1
2025-11-070
PRE